Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Rhythm Pharmaceuticals: Clinical Trials & FDA Approval Profile

Rhythm Pharmaceuticals (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (2 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)28 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Rhythm Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)5 (2)
Completed vs Stopped Early10 / 0 (0.0%)
Median Closed Actual Enrollment28 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Rhythm Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Columbia University Irving Medical CenterNew York, NY8
Children's Hospital ColoradoAurora, CO6
Vanderbilt University Medical CenterNashville, TN6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Rhythm Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06760546A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Phase IIIRECRUITING
NCT06046443A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Rhythm Pharmaceuticals Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI